Celsion Corporation Urges All Shareholders to Vote at the 2021 Annual Meeting to be Held on Friday June 4, 2021
02 juin 2021 08h00 HE
|
Celsion CORP
Calls for All Shareholders to Vote so Quorum Requirement to Hold The Meeting is Met LAWRENCEVILLE, N.J., June 02, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage...
Celsion Corporation Urges All Shareholders to Vote at the 2021 Annual Meeting to be Held on Friday June 4, 2021
27 mai 2021 08h30 HE
|
Celsion CORP
Calls for All Shareholders to Vote so Quorum Requirement to Hold The Meeting is Met LAWRENCEVILLE, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage...
Celsion Management Participates in Alliance Global Partners Virtual Series
22 avr. 2021 08h30 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., April 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced...
Celsion Corporation Reports 2020 Financial Results and Provides Business Update
19 mars 2021 08h45 HE
|
Celsion CORP
Entered 2021 with a Focus on Cancer Immunotherapy and Next-Generation Infectious Vaccines and a Strong Balance Sheet Conference Call Begins at 11:00 a.m. Eastern Time Today ...
Celsion Corporation to Hold Year-End 2020 Financial Results and Business Update Conference Call on Friday, March 19, 2021
12 mars 2021 08h45 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
Celsion Corporation Provides Clinical Update on Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer Including Encouraging Interim Resection Scores
25 févr. 2021 08h45 HE
|
Celsion CORP
Of 27 patients who completed interval debulking surgery, 80% of those treated with GEN-1 had an R0 resection compared with 58% of control patients, a 38% improvement To date 34 patients, or...